2022
DOI: 10.2174/156802662220220908152340
|View full text |Cite
|
Sign up to set email alerts
|

Advances in Drug Discovery based on Genomics, Proteomics and Bioinformatics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 4 publications
0
1
0
Order By: Relevance
“…The advancement in structure-based drug discovery is propelled by accessible multiomic, genomic, and proteomic data, which facilitates a faster, cost-efficient lead discovery. These multiomics technologies are unveiling novel druggable targets and enhancing the understanding of disease mechanisms, thereby broadening the spectrum of opportunities in drug discovery. , Predicting the free binding energy (affinity) from the protein–ligand atomic coordinates remains a challenge to date in computational chemistry. Drug discovery is surely going to benefit from the advances in this field of chemistry, thereby providing viable chemical compounds from the ever-evolving chemical spaces during virtual screening and thus advancing hit-to-lead optimization. , The process of screening active ligands involves several phases.…”
Section: Rational Drug Design Technologiesmentioning
confidence: 99%
“…The advancement in structure-based drug discovery is propelled by accessible multiomic, genomic, and proteomic data, which facilitates a faster, cost-efficient lead discovery. These multiomics technologies are unveiling novel druggable targets and enhancing the understanding of disease mechanisms, thereby broadening the spectrum of opportunities in drug discovery. , Predicting the free binding energy (affinity) from the protein–ligand atomic coordinates remains a challenge to date in computational chemistry. Drug discovery is surely going to benefit from the advances in this field of chemistry, thereby providing viable chemical compounds from the ever-evolving chemical spaces during virtual screening and thus advancing hit-to-lead optimization. , The process of screening active ligands involves several phases.…”
Section: Rational Drug Design Technologiesmentioning
confidence: 99%